The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial

Rationale: Augmentation therapy with intravenous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD). The recommended standard dose (SD; 60 mg/kg/wk) elevates AAT trough serum levels to around 50% of normal; however, outside of slo...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, Michael A., Geraghty, Patrick, Holt, Gregory, Mendes, Eliana, Newby, Paul R., Ma, Shuren, Luna-Diaz, Landy V., Turino, Gerard M., Stockley, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680306/
https://www.ncbi.nlm.nih.gov/pubmed/30965011
http://dx.doi.org/10.1164/rccm.201901-0010OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680306/
https://www.ncbi.nlm.nih.gov/pubmed/30965011
http://dx.doi.org/10.1164/rccm.201901-0010OC

Ejemplares similares